|
1
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar
|
|
2
|
Ahn SS, Shin NY, Chang JH, Kim SH, Kim EH,
Kim DW and Lee SK: Prediction of methylguanine methyltransferase
promoter methylation in glioblastoma using dynamic
contrast-enhanced magnetic resonance and diffusion tensor imaging.
J Neurosurg. 121:367–373. 2014. View Article : Google Scholar
|
|
3
|
Doniselli FM, Pascuzzo R, Agro M, Aquino
D, Anghileri E, Farinotti M, Pollo B, Paterra R, Cuccarini V,
Moscatelli M, et al: Development of A Radiomic Model for MGMT
Promoter Methylation Detection in Glioblastoma Using Conventional
MRI. Int J Mol Sci. 25:1382023. View Article : Google Scholar
|
|
4
|
Drabycz S, Roldan G, de Robles P, Adler D,
McIntyre JB, Magliocco AM, Cairncross JG and Mitchell JR: An
analysis of image texture, tumor location, and MGMT promoter
methylation in glioblastoma using magnetic resonance imaging.
Neuroimage. 49:1398–1405. 2010. View Article : Google Scholar
|
|
5
|
Han Y, Yan LF, Wang XB, Sun YZ, Zhang X,
Liu ZC, Nan HY, Hu YC, Yang Y, Zhang J, et al: Structural and
advanced imaging in predicting MGMT promoter methylation of primary
glioblastoma: A region of interest based analysis. BMC Cancer.
18:2152018. View Article : Google Scholar
|
|
6
|
Kanas VG, Zacharaki EI, Thomas GA, Zinn
PO, Megalooikonomou V and Colen RR: Learning MRI-based
classification models for MGMT methylation status prediction in
glioblastoma. Comput Methods Programs Biomed. 140:249–257. 2017.
View Article : Google Scholar
|
|
7
|
Sanada T, Kinoshita M, Sasaki T, Yamamoto
S, Fujikawa S, Fukuyama S, Hayashi N, Fukai J, Okita Y, Nonaka M,
et al: Prediction of MGMT promotor methylation status in
glioblastoma by Contrast-enhanced T1-weighted intensity image.
Neurooncol Adv. 6:vdae0162024.
|
|
8
|
Ozturk K, Soylu E and Cayci Z: Correlation
between dynamic susceptibility contrast perfusion MRI and genomic
alterations in glioblastoma. Neuroradiology. 63:1801–1810. 2021.
View Article : Google Scholar
|
|
9
|
Paech D, Windschuh J, Oberhollenzer J,
Dreher C, Sahm F, Meissner JE, Goerke S, Schuenke P, Zaiss M,
Regnery S, et al: Assessing the predictability of IDH mutation and
MGMT methylation status in glioma patients using
relaxation-compensated multipool CEST MRI at 7.0 T. Neuro Oncol.
20:1661–1671. 2018. View Article : Google Scholar
|
|
10
|
Ryoo I, Choi SH, Kim JH, Sohn CH, Kim SC,
Shin HS, Yeom JA, Jung SC, Lee AL, Yun TJ, et al: Cerebral blood
volume calculated by dynamic susceptibility contrast-enhanced
perfusion MR imaging: Preliminary correlation study with
glioblastoma genetic profiles. PLoS One. 8:e717042013. View Article : Google Scholar
|
|
11
|
Shen N, Zhang S, Cho J, Li S, Zhang J, Xie
Y, Wang Y and Zhu W: Application of cluster analysis of time
evolution for magnetic resonance Imaging-derived oxygen extraction
fraction mapping: A Promising strategy for the genetic profile
prediction and grading of glioma. Front Neurosci. 15:7368912021.
View Article : Google Scholar
|
|
12
|
Do DT, Yang MR, Lam LHT, Le NQK and Wu YW:
Improving MGMT methylation status prediction of glioblastoma
through optimizing radiomics features using genetic algorithm-based
machine learning approach. Sci Rep. 12:134122022. View Article : Google Scholar
|
|
13
|
Li ZC, Bai H, Sun Q, Li Q, Liu L, Zou Y,
Chen Y, Liang C and Zheng H: Multiregional radiomics features from
multiparametric MRI for prediction of MGMT methylation status in
glioblastoma multiforme: A multicentre study. Eur Radiol.
28:3640–3650. 2018. View Article : Google Scholar
|
|
14
|
Sasaki T, Kinoshita M, Fujita K, Fukai J,
Hayashi N, Uematsu Y, Okita Y, Nonaka M, Moriuchi S, Uda T, et al:
Radiomics and MGMT promoter methylation for prognostication of
newly diagnosed glioblastoma. Sci Rep. 9:144352019. View Article : Google Scholar
|
|
15
|
Xi YB, Guo F, Xu ZL, Li C, Wei W, Tian P,
Liu TT, Liu L, Chen G, Ye J, et al: Radiomics signature: A
potential biomarker for the prediction of MGMT promoter methylation
in glioblastoma. J Magn Reson Imaging. 47:1380–1387. 2018.
View Article : Google Scholar
|
|
16
|
Lu J, Li X and Li H: Perfusion parameters
derived from MRI for preoperative prediction of IDH mutation and
MGMT promoter methylation status in glioblastomas. Magn Reson
Imaging. 83:189–195. 2021. View Article : Google Scholar
|
|
17
|
Fuster-Garcia E, Lorente Estelles D,
Alvarez-Torres MDM, Juan-Albarracin J, Chelebian E, Rovira A,
Acosta CA, Pineda J, Oleaga L, Molla-Olmos E, et al: MGMT
methylation may benefit overall survival in patients with
moderately vascularized glioblastomas. Eur Radiol. 31:1738–1747.
2021. View Article : Google Scholar
|
|
18
|
Moon WJ, Choi JW, Roh HG, Lim SD and Koh
YC: Imaging parameters of high grade gliomas in relation to the
MGMT promoter methylation status: The CT, diffusion tensor imaging,
and perfusion MR imaging. Neuroradiology. 54:555–563. 2012.
View Article : Google Scholar
|
|
19
|
Bonekamp D, Deike K, Wiestler B, Wick W,
Bendszus M, Radbruch A and Heiland S: Association of overall
survival in patients with newly diagnosed glioblastoma with
contrast-enhanced perfusion MRI: Comparison of intraindividually
matched T1-and T2 (*)-based bolus techniques. J Magn Reson Imaging.
42:87–96. 2015. View Article : Google Scholar
|
|
20
|
Hirai T, Murakami R, Nakamura H, Kitajima
M, Fukuoka H, Sasao A, Akter M, Hayashida Y, Toya R, Oya N, et al:
Prognostic value of perfusion MR imaging of high-grade
astrocytomas: Long-term Follow-up study. AJNR Am J Neuroradiol.
29:1505–1510. 2008. View Article : Google Scholar
|
|
21
|
Jain R, Poisson L, Narang J, Gutman D,
Scarpace L, Hwang SN, Holder C, Wintermark M, Colen RR, Kirby J, et
al: Genomic mapping and survival prediction in glioblastoma:
Molecular subclassification strengthened by hemodynamic imaging
biomarkers. Radiology. 267:212–220. 2013. View Article : Google Scholar
|
|
22
|
Law M, Young RJ, Babb JS, Peccerelli N,
Chheang S, Gruber ML, Miller DC, Golfinos JG, Zagzag D and Johnson
G: Gliomas: Predicting time to progression or survival with
cerebral blood volume measurements at dynamic
Susceptibility-weighted Contrast-enhanced perfusion MR imaging.
Radiology. 247:490–498. 2008. View Article : Google Scholar
|
|
23
|
Alvarez-Torres MDM, Fuster-Garcia E,
Balana C, Puig J and Garcia-Gomez JM: Lack of benefit of extending
temozolomide treatment in patients with high vascular glioblastoma
with methylated MGMT. Cancers (Basel). 13:2021. View Article : Google Scholar
|
|
24
|
Goldman J, Hagiwara A, Yao J, Raymond C,
Ong C, Bakhti R, Kwon E, Farhat M, Torres C, Erickson LG, et al:
Paradoxical association between relative cerebral blood volume
dynamics following chemoradiation and increased Progression-free
survival in newly diagnosed IDH Wild-Type MGMT promoter methylated
glioblastoma with measurable disease. Front Oncol. 12:8499932022.
View Article : Google Scholar
|
|
25
|
Shen N, Zhao L, Jiang J, Jiang R, Su C,
Zhang S, Tang X and Zhu W: Intravoxel incoherent motion
Diffusion-weighted imaging analysis of diffusion and microperfusion
in grading gliomas and comparison with arterial spin labeling for
evaluation of tumor perfusion. J Magn Reson Imaging. 44:620–632.
2016. View Article : Google Scholar
|
|
26
|
Wang X, Chen XZ, Shi L and Dai JP: Glioma
grading and IDH1 mutational status: Assessment by intravoxel
incoherent motion MRI. Clin Radiol. 74:651.e7–651.e14. 2019.
View Article : Google Scholar
|
|
27
|
Okita Y, Nonaka M, Shofuda T, Kanematsu D,
Yoshioka E, Kodama Y, Mano M, Nakajima S and Kanemura Y:
(11)C-methinine uptake correlates with MGMT promoter methylation in
nonenhancing gliomas. Clin Neurol Neurosurg. 125:212–216. 2014.
View Article : Google Scholar
|
|
28
|
Sasaki T, Fukai J, Kodama Y, Hirose T,
Okita Y, Moriuchi S, Nonaka M, Tsuyuguchi N, Terakawa Y, Uda T, et
al: Characteristics and outcomes of elderly patients with diffuse
gliomas: A Multi-institutional cohort study by Kansai Molecular
Diagnosis Network for CNS tumors. J Neurooncol. 140:329–339. 2018.
View Article : Google Scholar
|
|
29
|
Juan-Albarracin J, Fuster-Garcia E,
Perez-Girbes A, Aparici-Robles F, Alberich-Bayarri A,
Revert-Ventura A, Marti-Bonmati L and Garcia-Gomez JM:
Glioblastoma: Vascular habitats detected at preoperative dynamic
susceptibility-weighted Contrast-enhanced perfusion MR imaging
predict survival. Radiology. 287:944–954. 2018. View Article : Google Scholar
|
|
30
|
Song S, Shan Y, Wang L, Cheng Y, Yang H,
Zhao G, Wang Z and Lu J: MGMT promoter methylation status shows no
effect on [(18)F]FET uptake and CBF in gliomas: A stereotactic
Image-based histological validation study. Eur Radiol.
32:5577–5587. 2022. View Article : Google Scholar
|
|
31
|
Onnis B, Rapisarda A and Melillo G:
Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med.
13:2780–2786. 2009. View Article : Google Scholar
|
|
32
|
Li L, Lin X, Shoemaker AR, Albert DH,
Fesik SW and Shen Y: Hypoxia-inducible Factor-1 inhibition in
combination with temozolomide treatment exhibits robust antitumor
efficacy in vivo. Clin Cancer Res. 12:4747–4754. 2006. View Article : Google Scholar
|
|
33
|
Tang JH, Ma ZX, Huang GH, Xu QF, Xiang Y,
Li N, Sidlauskas K, Zhang EE and Lv SQ: Downregulation of HIF-1a
sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
Exp Cell Res. 343:148–158. 2016. View Article : Google Scholar
|
|
34
|
Persano L, Pistollato F, Rampazzo E, Della
Puppa A, Abbadi S, Frasson C, Volpin F, Indraccolo S, Scienza R and
Basso G: BMP2 sensitizes glioblastoma Stem-like cells to
Temozolomide by affecting HIF-1α stability and MGMT expression.
Cell Death Dis. 3:e4122012. View Article : Google Scholar
|
|
35
|
Burth S, Kickingereder P, Eidel O, Tichy
D, Bonekamp D, Weberling L, Wick A, Low S, Hertenstein A,
Nowosielski M, et al: Clinical parameters outweigh Diffusion- and
Perfusion-derived MRI parameters in predicting survival in newly
diagnosed glioblastoma. Neuro Oncol. 18:1673–1679. 2016. View Article : Google Scholar
|
|
36
|
Gerstner ER, Zhang Z, Fink JR, Muzi M,
Hanna L, Greco E, Prah M, Schmainda KM, Mintz A, Kostakoglu L, et
al: ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed
glioblastoma using 18F-FMISO PET and MRI. Clin Cancer Res.
22:5079–5086. 2016. View Article : Google Scholar
|
|
37
|
Paik W, Kim HS, Choi CG and Kim SJ:
Pre-operative perfusion skewness and kurtosis are potential
predictors of Progression-free survival after partial resection of
newly diagnosed glioblastoma. Korean J Radiol. 17:117–126. 2016.
View Article : Google Scholar
|
|
38
|
White ML, Zhang Y, Kazmi SAJ, Aizenberg M,
Shonka N, Yu F and Appiah AK: Evaluating survival in subjects with
astrocytic brain tumors by dynamic Susceptibility-weighted
perfusion MR imaging. PLoS One. 16:e02442752021. View Article : Google Scholar
|
|
39
|
Batchelor TT, Gerstner ER, Emblem KE, Duda
DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho
MC, Jennings D, et al: Improved tumor oxygenation and survival in
glioblastoma patients who show increased blood perfusion after
cediranib and chemoradiation. Proc Natl Acad Sci USA.
110:19059–19064. 2013. View Article : Google Scholar
|
|
40
|
Willan AR and Pinto EM: The value of
information and optimal clinical trial design. Stat Med.
24:1791–1806. 2005. View Article : Google Scholar
|
|
41
|
Zhang L, Cui L and Yang B: Optimal
flexible sample size design with robust power. Stat Med.
35:3385–3396. 2016. View Article : Google Scholar
|
|
42
|
Nagahama H, Shonai T, Takashima H, Hirano
T, Suzuki J and Sakurai Y: MRI of Perfusion: Principles and
Clinical Applications. Igaku Butsuri. 36:103–109. 2016.(In
Japanese).
|
